Fmr LLC Phathom Pharmaceuticals, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Fmr LLC holds 2,656 shares of PHAT stock, worth $44,780. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,656

Previous 2,084 27.45%

Holding current value

$44,780

Previous $22,000 22.73%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$8.97 - $12.05 $5,130 - $6,892	572 Added 27.45%	2,656 $27,000
Q1 2024 May 13, 2024	SELL	$6.21 - $11.05 $7,756 - $13,801	-1,249 Reduced 37.47%	2,084 $22,000
Q4 2023 Feb 13, 2024	BUY	$6.99 - $10.71 $10,093 - $15,465	1,444 Added 76.44%	3,333 $30,000
Q3 2023 Nov 13, 2023	SELL	$10.26 - $15.7 $363,563 - $556,329	-35,435 Reduced 94.94%	1,889 $19,000
Q2 2023 Aug 11, 2023	BUY	$7.28 - $14.32 $266,127 - $523,481	36,556 Added 4759.9%	37,324 $534,000
Q1 2023 May 11, 2023	BUY	$6.19 - $12.36 $451 - $902	73 Added 10.5%	768 $5,000
Q4 2022 Feb 13, 2023	SELL	$9.18 - $11.53 $4,773 - $5,995	-520 Reduced 42.8%	695 $7,000
Q3 2022 Nov 10, 2022	BUY	$6.46 - $12.11 $5,407 - $10,136	837 Added 221.43%	1,215 $13,000
Q2 2022 Aug 12, 2022	SELL	$6.2 - $15.5 $651 - $1,627	-105 Reduced 21.74%	378 $3,000
Q1 2022 May 13, 2022	BUY	$11.55 - $20.06 $5,578 - $9,688	483 New	483 $7,000
Q4 2021 Feb 14, 2022	SELL	$17.83 - $33.15 $2.75 Million - $5.11 Million	-154,200 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$30.69 - $36.83 $4.73 Million - $5.68 Million	154,200 New	154,200 $4.95 Million

Others Institutions Holding PHAT

# of Institutions

128

Shares Held

62.7M

Call Options Held

467K

Put Options Held

34.9K

View Full List

About Phathom Pharmaceuticals, Inc.

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $660M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

More about PHAT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account